Shares of Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) were down 3.4% during mid-day trading on Thursday . The stock traded as low as $15.01 and last traded at $14.80. Approximately 99,122 shares traded hands during trading, a decline of 46% from the average daily volume of 184,770 shares. The stock had previously closed at $15.32.
Wall Street Analyst Weigh In
Separately, Wall Street Zen upgraded Pulse Biosciences to a "sell" rating in a research report on Monday, March 31st.
Read Our Latest Research Report on Pulse Biosciences
Pulse Biosciences Price Performance
The company has a 50 day simple moving average of $16.51 and a 200-day simple moving average of $17.55.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.25) earnings per share for the quarter.
Insider Activity
In related news, CTO Darrin Uecker sold 15,000 shares of Pulse Biosciences stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $16.40, for a total value of $246,000.00. Following the completion of the sale, the chief technology officer directly owned 137,872 shares in the company, valued at $2,261,100.80. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 71.50% of the company's stock.
Hedge Funds Weigh In On Pulse Biosciences
Institutional investors have recently bought and sold shares of the business. Rhumbline Advisers lifted its holdings in Pulse Biosciences by 6.3% during the first quarter. Rhumbline Advisers now owns 27,375 shares of the company's stock worth $440,000 after buying an additional 1,614 shares during the period. Strs Ohio purchased a new stake in shares of Pulse Biosciences during the 1st quarter worth $286,000. Jane Street Group LLC bought a new stake in Pulse Biosciences during the first quarter valued at about $323,000. Panoramic Capital LLC grew its stake in Pulse Biosciences by 8.5% in the first quarter. Panoramic Capital LLC now owns 52,723 shares of the company's stock valued at $848,000 after purchasing an additional 4,152 shares during the last quarter. Finally, AlphaQuest LLC grew its stake in Pulse Biosciences by 68.0% in the first quarter. AlphaQuest LLC now owns 3,116 shares of the company's stock valued at $50,000 after purchasing an additional 1,261 shares during the last quarter. 76.95% of the stock is owned by hedge funds and other institutional investors.
Pulse Biosciences Company Profile
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Read More
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
